Advertisement

Patterns of Oral PrEP Adherence and HIV Risk Among Eastern African Women in HIV Serodiscordant Partnerships

  • Maria Pyra
  • Elizabeth R. Brown
  • Jessica E. Haberer
  • Renee Heffron
  • Connie Celum
  • Elizabeth A. Bukusi
  • Stephen Asiimwe
  • Elly Katabira
  • Nelly R. Mugo
  • Jared M. Baeten
  • for the Partners Demonstration Project Team
Original Paper
  • 36 Downloads

Abstract

Understanding how women use PrEP is important for developing successful implementation programs. We hypothesized there are distinct patterns of adherence, related to HIV risk and other factors. We identified patterns of PrEP adherence and HIV risk behavior over the first 6 months of PrEP use, using data from 233 HIV-uninfected women in high-risk serodiscordant couples in a demonstration project in Kenya & Uganda. We modeled PrEP adherence, assessed by daily electronic monitoring, and HIV risk behavior using group-based trajectory models. We tested baseline covariates and risk behavior group as predictors of adherence patterns. There were four distinct adherence patterns: high steady adherence (55% of population), moderate steady (29%), late declining (8%), and early declining (9%). No baseline characteristics significantly differed between adherence patterns. Adherence patterns differed in average weekly doses (6.7 vs 5.4 vs 4.1 vs 1.5, respectively). Two risk behavior groups were identified: steady HIV risk (78% of population) and declining (22%). Compared to women with declining HIV risk behavior, women with steady risk behavior were more likely to have high steady adherence (61% vs 35%) and less likely to have early (6% vs 17%) or late (4% vs 19%) declining adherence. Women’s use of PrEP was associated with concurrent HIV risk behavior; higher risk was associated with higher, sustained adherence.

Keywords

Pre-exposure prophylaxis HIV Adherence Patterns Women Africa 

Notes

Acknowledgements

We thank the couples who participated in this study. Jared Baeten (protocol chair), Connie Celum (protocol co-chair), Renee Heffron (project director), Deborah Donnell (statistician), Ruanne Barnabas, Jessica Haberer, Harald Haugen, Craig Hendrix, Lara Kidoguchi, Mark Marzinke, Susan Morrison, Jennifer Morton, Norma Ware, Monique Wyatt. Project sites: Kabwohe, Uganda (Kabwohe Clinical Research Centre): Stephen Asiimwe, Edna Tindimwebwa. Kampala, Uganda (Makerere University): Elly Katabira, Nulu Bulya. Kisumu, Kenya (Kenya Medical Research Institute): Elizabeth Bukusi, Josephine Odoyo. Thika, Kenya (Kenya Medical Research Institute, University of Washington): Nelly Rwamba Mugo, Kenneth Ngure. Data Management was provided by DF/Net Research, Inc. (Seattle, WA). PrEP medication was donated by Gilead Sciences.

Funding

The Partners Demonstration Project was funded by the National Institute of Mental Health of the US National Institutes of Health (R01 MH095507), the Bill & Melinda Gates Foundation (OPP1056051), and the US Agency for International Development (AID-OAA-A-12-00023). Additional funding for the present analysis came from the National Institute of Mental Health (R01 MH098744). The contents are the responsibility of the authors and do not necessarily reflect the views of USAID, NIH, or the United States Government.

Compliance with Ethical Standards

Conflict of interest

JMB has led studies with pre-exposure prophylaxis medication donated by Gilead Sciences and served on an advisory committee.

Ethical Approval and Informed Consent

The University of Washington Human Subjects Division and ethics review committees at each site (the National HIV/AIDS Research Committee of the Uganda National Council for Science and Technology or the Ethics Review Committee of the Kenya Medical Research Institute) approved the protocol. All participants provided written informed consent in their preferred language in accordance with the Declaration of Helsinki.

Supplementary material

10461_2018_2221_MOESM1_ESM.docx (25 kb)
Supplementary material 1 (DOCX 25 kb)

References

  1. 1.
    AIDS by the Numbers. Geneva, Switzerland: UNAIDS; 2016. http://www.unaids.org/sites/default/files/media_asset/AIDS-by-the-numbers-2016_en.pdf. Accessed 29 Nov 2017.
  2. 2.
    Prevention Gap Report. Geneva, Switzerland: UNAIDS; 2016. http://www.unaids.org/sites/default/files/media_asset/2016-prevention-gap-report_en.pdf. Accessed 29 Nov 2017.
  3. 3.
    Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367:411–22.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372:509–18.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Corneli A, Perry B, McKenna K, Agot K, Ahmed K, Taylor J, et al. Participants’ explanations for non-adherence in the FEM-PrEP clinical trial. J Acquir Immune Defic Syndr. 2016;71(4):452–61.CrossRefPubMedGoogle Scholar
  6. 6.
    van der Straten A, Stadler J, Montgomery E, Hartmann M, Magazi B, Mathebula F, et al. Women’s experiences with oral and vaginal pre-exposure prophylaxis: the VOICE-C Qualitative Study in Johannesburg, South Africa. PLoS ONE. 2014;9(2):e89118.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399–410.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Murnane PM, Celum C, Mugo N, Campbell JD, Donnell D, Bukusi E, et al. Efficacy of pre-exposure prophylaxis for HIV-1 prevention among high risk heterosexuals: subgroup analyses from the Partners PrEP Study. AIDS Lond Engl. 2013;27(13):2155–60.CrossRefGoogle Scholar
  9. 9.
    Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367:423–34.CrossRefPubMedGoogle Scholar
  10. 10.
    Baeten JM, Heffron R, Kidoguchi L, Mugo NR, Katabira E, Bukusi EA, et al. Integrated delivery of antiretroviral treatment and pre-exposure prophylaxis to HIV-1-serodiscordant couples: a prospective implementation study in Kenya and Uganda. PLoS Med. 2016;13:e1002099.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Bekker L-G, Roux S, Sebastien E, Yola N, Amico KR, Hughes JP, et al. Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial. Lancet HIV. 2017.  https://doi.org/10.1016/S2352-3018(17)30156-X.PubMedGoogle Scholar
  12. 12.
    Amico KR, Wallace M, Bekker L-G, Roux S, Atujuna M, Sebastian E, et al. Experiences with HPTN 067/ADAPT study-provided open-label PrEP among women in Cape Town: facilitators and barriers within a mutuality framework. AIDS Behav. 2017;21(5):1361–75.CrossRefPubMedGoogle Scholar
  13. 13.
    Patel RC, Stanford-Moore G, Odoyo J, Pyra M, Wakhungu I, Anand K, et al. “Since both of us are using antiretrovirals, we have been supportive to each other”: facilitators and barriers of pre-exposure prophylaxis use in heterosexual HIV discordant couples in Kisumu, Kenya. JIAS. 2016;19(1):21134.CrossRefGoogle Scholar
  14. 14.
    Haberer JE, Bangsberg DR, Baeten JM, Curran K, Koechlin F, Amico KR, et al. Defining success with HIV pre-exposure prophylaxis: a prevention-effective adherence paradigm. AIDS. 2015;29:1277–85.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Haberer JE, Kidoguchi L, Heffron R, Mugo N, Bukusi E, Katabira E, et al. Alignment of adherence and risk for HIV acquisition in a demonstration project of pre-exposure prophylaxis among HIV serodiscordant couples in Kenya and Uganda: a prospective analysis of prevention-effective adherence. J Int AIDS Soc. 2017;20:1–9.Google Scholar
  16. 16.
    Kahle EM, Hughes JP, Lingappa JR, John-Stewart G, Celum C, Nakku-Joloba E, et al. An empiric risk scoring tool for identifying high-risk heterosexual HIV-1 serodiscordant couples for targeted HIV-1 prevention. J Acquir Immune Defic Syndr. 2013;62:339–47.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Irungu EM, Heffron R, Mugo N, Ngure K, Katabira E, Bulya N, et al. Use of a risk scoring tool to identify higher-risk HIV-1 serodiscordant couples for an antiretroviral-based HIV-1 prevention intervention. BMC Infect Dis. 2016;16(1):571.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Glass TR, Battegay M, Cavassini M, De Geest S, Furrer H, Vernazza PL, et al. Longitudinal analysis of patterns and predictors of changes in self-reported adherence to antiretroviral therapy: Swiss HIV Cohort Study. J Acquir Immune Defic Syndr. 2010;54:197–203.PubMedGoogle Scholar
  19. 19.
    Pines HA, Gorbach PM, Weiss RE, Shoptaw S, Landovitz RJ, Javanbakht M, et al. Sexual risk trajectories among MSM in the United States: implications for pre-exposure prophylaxis delivery. J Acquir Immune Defic Syndr. 2014;65:579–86.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Nagin DS. Group-based modeling of development. Cambridge: Harvard University Press; 2005.CrossRefGoogle Scholar
  21. 21.
    Jones BL. traj: group-based modeling of longitudinal data. Traj Group-Based Model Longitud Data. https://www.andrew.cmu.edu/user/bjones/index.htm. Accessed 25 Apr 2018.
  22. 22.
    Jones BL, Nagin DS. Advances in group-based trajectory modeling and an SAS procedure for estimating them. Sociol Methods Res. 2007;35:542–71.CrossRefGoogle Scholar
  23. 23.
    Nagin DS, Tremblay RE. Developmental trajectory groups: fact or a useful statistical fiction?*. Criminology. 2005;43:873–904.CrossRefGoogle Scholar
  24. 24.
    Nagin DS, Odgers CL. Group-based trajectory modeling in clinical research. Annu Rev Clin Psychol. 2010;6:109–38.CrossRefPubMedGoogle Scholar
  25. 25.
    Jones BL, Nagin DS, Roeder K. A SAS procedure based on mixture models for estimating developmental trajectories. Sociol Methods Res. 2001;29:374–93.CrossRefGoogle Scholar
  26. 26.
    Blumenthal J, Jain S, Dube M, Sun X, Ellorin E, Hoenigl M, et al. Recent HIV Risk Behavior and Partnership Type predict PrEP adherence in men who have sex with men. San Diego, CA; 2017. https://idsa.confex.com/idsa/2017/viewsessionpdf.cgi. Accessed 8 Dec 2017.
  27. 27.
    Napper LE, Fisher DG, Reynolds GL. Development of the perceived risk of HIV scale. AIDS Behav. 2012;16:1075–83.CrossRefPubMedGoogle Scholar
  28. 28.
    Bradley H, Tsui A, Hindin M, Kidanu A, Gillespie D. Developing scales to measure perceived HIV risk and vulnerability among Ethiopian women testing for HIV. AIDS Care. 2011;23:1043–52.CrossRefPubMedGoogle Scholar
  29. 29.
    Carroll JJ, Heffron R, Mugo N, Ngure K, Ndase P, Asiimwe S, et al. Perceived risk among human immunodeficiency virus serodiscordant couples in East Africa taking oral pre-exposure prophylaxis. Sex Transm Dis. 2016;43:471–5.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Donnell D, Baeten JM, Bumpus NN, Brantley J, Bangsberg DR, Haberer JE, et al. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr. 2014;66:340–8.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Musinguzi N, Muganzi CD, Boum Y, Ronald A, Marzinke MA, Hendrix CW, et al. Comparison of subjective and objective adherence measures for pre-exposure prophylaxis against HIV infection among serodiscordant couples in East Africa. AIDS Lond Engl. 2016;30(7):1121.CrossRefGoogle Scholar
  32. 32.
    Mugwanya KK, Donnell D, Celum C, Thomas KK, Ndase P, Mugo N, et al. Sexual behavior of heterosexual men and women receiving antiretroviral pre-exposure prophylaxis for HIV prevention: a longitudinal analysis. Lancet Infect Dis. 2013;13:1021–8.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Maria Pyra
    • 1
    • 2
  • Elizabeth R. Brown
    • 3
    • 6
  • Jessica E. Haberer
    • 7
    • 8
  • Renee Heffron
    • 1
    • 2
  • Connie Celum
    • 1
    • 2
    • 5
  • Elizabeth A. Bukusi
    • 2
    • 4
    • 9
  • Stephen Asiimwe
    • 10
  • Elly Katabira
    • 11
  • Nelly R. Mugo
    • 2
    • 9
  • Jared M. Baeten
    • 1
    • 2
    • 5
  • for the Partners Demonstration Project Team
  1. 1.Department of EpidemiologyUniversity of WashingtonSeattleUSA
  2. 2.Department of Global HealthUniversity of WashingtonSeattleUSA
  3. 3.Department of BiostatisticsUniversity of WashingtonSeattleUSA
  4. 4.Department of Obstetrics and GynecologyUniversity of WashingtonSeattleUSA
  5. 5.Department of MedicineUniversity of WashingtonSeattleUSA
  6. 6.Vaccine and Infection Diseases and Public Health Science DivisionFred Hutchinson Cancer Research CenterSeattleUSA
  7. 7.Massachusetts General Hospital Global HealthBostonUSA
  8. 8.Department of MedicineHarvard Medical SchoolBostonUSA
  9. 9.Kenya Medical Research Institute (KEMRI)NairobiKenya
  10. 10.Kabwohe Clinical Research CenterKabwoheUganda
  11. 11.Infectious Disease Institute, Makerere UniversityKampalaUganda

Personalised recommendations